均衡的EGFR和微管类双抑制剂的设计
Yifan Liu1, Qiuya Ma2, Xiangyu Kong1
1Department of Medicinal Chemistry, Hebei Medical University, Shijiazhuang, China.
Bioorganic chemistry
|January 5, 2024
概括
一种新型的双抑制剂,化合物10c,有效地向EGFR激酶和微管聚合. 这种有前途的抗癌剂在临床前模型中显示出显著的疗效,因此需要进一步研究瘤治疗.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 将氨酸激酶抑制剂与向微管体的药物结合起来,在癌症治疗中取得了临床成功.
- 开发双位抑制剂为增强抗瘤疗效提供了一种新的策略.
研究的目的:
- 设计和合成新型双抑制剂与甲基urea-coupled quinazoline骨干.
- 评估合成化合物的体外和体内抗癌活性,重点关注化合物10c.
主要方法:
- 新型基纳林基化合物的合成和特征.
- 试验室生物评估包括细胞毒性,激酶抑制和基于细胞的测定 (蛋白聚合,细胞亡,细胞循环,迁移).
- 在A549携带癌症的裸体小鼠模型中的体内疗效研究.
主要成果:
- 化合物10c在体外对十种瘤细胞系 (IC50:1.047.66μM) 显示出广泛的有效性.
- 10c表现出优越的EGFR激酶抑制 (IC50: 10.66nM) 与Gefitinib (25.42nM) 相比,降低了下游信号 (p-EGFR,p-AKT,p-ERK).
- 10c显著抑制了管聚合,破坏了微管网,诱导了亡,导致S相停止,并阻碍了细胞迁移,体内疗效与半剂量的Gefitinib相当.
结论:
- 化合物10c是一种强大的双抑制剂,有效对抗EGFR和微管.
- 10c在体外和体内表现出显著的抗癌活性,显示出作为治疗候选人的希望.
- 这种新型的甲基urea-coupled quinazoline 支架代表了开发先进抗癌药物的可行平台.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.8K
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Destabilization of Microtubules
2.7K
The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
